Standard Biotools Inc Receivables Turnover Ratio (LAB), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Standard Biotools Inc   (NASDAQ: LAB)
 

Standard Biotools Inc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Standard Biotools Inc 's ability to collect accounts receivable sequentially worsen to 5.64, pointing to a challenging and on top of that deteriorating business climate for the Laboratory Analytical Instruments industry. Standard Biotools Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 65 days, from 62 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 334 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2037 to 2315.

What is Receivable Turnover Ratio?
What is Standard Biotools Inc Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LAB Receivables Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Receivable Change 7.77 % -53.11 % -8.89 % -61.67 % -54.96 %
Y / Y Revenue Change -7.05 % -50.15 % -50.33 % -55.98 % -41.4 %
Receivable Turnover Ratio (TTM) 5.64 5.86 5.48 6.62 6.17
LAB's Total Ranking # 2315 # 2037 # 2676 # 2369 # 2477
Accounts Receivable average collection period days 65 62 67 55 59
Seq. Receivable Change -5.35 % 23.87 % -0.78 % -7.36 % -58.82 %
Seq. Revenue Change -1 % -14.65 % 22.13 % -9.91 % -46.91 %


Receivable Turnover Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 14
Healthcare Sector # 335
Overall Market # 2315

Receivable Turnover Ratio Statistics
High Average Low
8.38 6.36 4.88
(Mar 31 2021)   (Dec 31 2012)




  News about Standard Biotools Inc Receivables Turnover Ratios

Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)

Comprehensive Proteomics Profiling Unveils Novel Biomarkers and Insights into Nonalcoholic Steatohepatitis (NASH)Interest in nonalcoholic steatohepatitis (NASH) has burgeoned in recent years as researchers deepen their understanding of its pathophysiology and resultant clinical sequelae. NASH, a severe form of nonalcoholic fatty liver disease (NAFLD), is characterized by liver inflammation and damage due to fat accumulation, potentially progressing to cirrhosis or liver cancer. Despite advances in clinical research, the molecular underpinnings of NASH remain elusive, posing significant barriers to the development of effective diagnostics and therapeutics. Recent advancements in proteomics, particularly through efforts spearheaded by Standard BioTools, have illustrated a promising avenue for unveiling unique biomarkers and new insights into this complex disease. Proteomics: An Essential Tool for NASH ResearchProteomics, the large-scale study of proteins, offers a powerful lens through which to dissect the molecular mechanisms underlying diseases such as NASH. Unlike genomics, which focuses on the relatively static blueprint of DNA, proteomics examines the dynamic, functional entities that actually drive biological processes. Proteins constitute the biomolecular machinery of cells and tissues, making proteomics instrumental in understanding disease processes, identifying biomarkers, and elucidating therapeutic targets.


LAB Company Profile • Back to LAB Efficiency Comparisons • Compare LAB Receivables Turnover Ratio to its Competitors

Financial Statements
Standard Biotools Inc 's Accounts Receivable $ 16 Millions Visit LAB's Balance sheet
Standard Biotools Inc 's Sales TTM $ 84 Millions Visit LAB's Income Statement
Sources of LAB's Revenues Visit LAB's Sales by Geography

Other Accounts Receivable Turnover Ratios
Laboratory Analytical Instruments Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
LAB's Receivable Turnover Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
LAB's Growth Rates LAB's Roa LAB's Inventory Turnover Ratio LAB's Dividend Comparisons
LAB's Profitability Ratios LAB's Roi LAB's Asset Turnover Ratio LAB's Dividend Growth
LAB's Valuation Ratios LAB's Roe LAB's Financial Strength Ratios LAB's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
Nexgel Inc   14.52 $ 11.810  Millions$ 0.813  Millions
Skinhealth Systems Inc   14.42 $ 289.224  Millions$ 20.051  Millions
Lftd Partners Inc   14.13 $ 35.335  Millions$ 2.500  Millions
Talkspace Inc   14.09 $ 246.631  Millions$ 17.506  Millions
Lifestance Health Group Inc   14.07 $ 1,584.834  Millions$ 112.665  Millions
10x Genomics Inc   13.90 $ 616.566  Millions$ 44.342  Millions
Amneal Pharmaceuticals Inc   13.90 $ 3,117.474  Millions$ 224.342  Millions
Ataibeckley Inc   13.83 $ 4.473  Millions$ 0.324  Millions
Corcept Therapeutics Inc  13.54 $ 830.813  Millions$ 61.352  Millions
Rosecliff Acquisition Corp I  13.43 $ 16.467  Millions$ 1.226  Millions
Precipio inc   13.25 $ 27.198  Millions$ 2.052  Millions
Chemed Corporation  12.94 $ 2,595.001  Millions$ 200.565  Millions
Qhslab Inc   12.77 $ 3.017  Millions$ 0.236  Millions
Nrc Health  12.72 $ 139.996  Millions$ 11.004  Millions
Mannkind Corporation  12.39 $ 393.630  Millions$ 31.773  Millions
Petvivo Holdings Inc   12.34 $ 1.182  Millions$ 0.096  Millions
Siga Technologies Inc  12.32 $ 53.659  Millions$ 4.356  Millions
Alpha Pro Tech Ltd   12.25 $ 62.204  Millions$ 5.077  Millions
Vivos Therapeutics Inc   12.21 $ 21.135  Millions$ 1.731  Millions
Milestone Scientific Inc   11.98 $ 8.855  Millions$ 0.739  Millions
Teladoc Health Inc   11.88 $ 2,489.480  Millions$ 209.556  Millions
Premier Air Charter Holdings Inc   11.72 $ 31.562  Millions$ 2.692  Millions
Catheter Precision Inc   11.62 $ 1.915  Millions$ 0.165  Millions
Icu Medical Inc  11.42 $ 2,159.998  Millions$ 189.166  Millions
National Healthcare Corp  11.40 $ 1,559.020  Millions$ 136.723  Millions
Picard Medical Inc   11.34 $ 5.983  Millions$ 0.528  Millions
Vaso Corporation  11.31 $ 80.220  Millions$ 7.094  Millions
Innoviva Inc   11.22 $ 420.630  Millions$ 37.491  Millions
Lifeloc Technologies Inc   11.19 $ 9.269  Millions$ 0.828  Millions
Veracyte Inc   11.07 $ 544.735  Millions$ 49.194  Millions

Date modified: 2026-09-01T20:00:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.